Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00381212
Other study ID # BMB#06-003
Secondary ID CAN-HIV-001CTN22
Status Completed
Phase Phase 1/Phase 2
First received September 25, 2006
Last updated January 28, 2009
Start date September 2006
Est. completion date November 2008

Study information

Verified date January 2009
Source McGill University Health Center
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

To Investigate the safety and immunologic activity of AGS-004, an autologous HIV Immunotherapeutic, in HIV-infected adults currently on stable antiretroviral therapy (ART) with durable viral suppression.


Description:

Although an HIV infection can induce weak immune responses, current HIV immunotherapy using consensus antigens has not shown consistent clinical activity. The absence of clinical activity is associated with an inability to raise cytotoxic T lymphocytes (CTL) against HIV antigens and a failure to induce T cell memory. While strong immune responses may be generated to a consensus antigen, those responses do not offer antiviral protection against a patient's individual viral burden. The infecting virus' antigen variability likely prevents the establishment of effective CD4+ T cell memory and a strong CD8+ T cell effector arm.

We are investigating the induction of CTL responses in HIV-infected subjects by a novel HIV immunotherapeutic agent (AGS-004) in an effort to overcome the lack of polyvalent specificity of the immune response for autologous HIV antigens which has been one of the primary reasons for the failure of HIV immunotherapy to date.

This pilot study will investigate the safety and immunologic activity of AGS-004 an autologous HIV immunotherapeutic agent.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date November 2008
Est. primary completion date February 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Men or women age 18 years and over,

- Documented HIV-1 infection,

- Durable viral suppression (= 200 copies HIV-1 RNA / mL) on first ART regimen for at least 12 weeks prior to entry,

- Availability of = 2.5mL of continually-frozen plasma before starting ART (=30,000 copies/mL),

- CD4+ T cell count =200 cells/mm3 at time of pre-ART sample,

- CD4+ T cell count of =350 cells/mm3 obtained within 4 weeks of study entry,

Exclusion Criteria:

- No co-infection with HBV or HCV,

- No history of lymph node irradiation or dissection,

- No prior use of any HIV vaccine,

- No use of hydroxyurea,

- No use of systemic corticosteroids or other non-permitted medications,

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
AGS-004
Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.

Locations

Country Name City State
Canada Immunodeficiency Service/Montreal Chest Institute Montreal Quebec

Sponsors (3)

Lead Sponsor Collaborator
McGill University Health Center Argos Therapeutics, Université de Montréal

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunologic activity of AGS-004 will be as measured by flow cytometry 18 weeks No
Secondary To determine the safety of AGS-004 in the entire study population by frequency and severity of treatment emergent adverse events 66 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT01968551 - Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults Phase 3
Completed NCT02929069 - A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk N/A
Recruiting NCT02392884 - HIV Medication Adherence in Underserved Populations N/A
Completed NCT02583464 - Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg. Phase 1
Completed NCT02264509 - Peripheral Arterial Insufficiency Associated With HIV/AIDS N/A
Completed NCT01440569 - Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults Phase 3
Completed NCT00551330 - Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED) Phase 2
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT00001409 - Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications Phase 1
Completed NCT00000590 - Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) Phase 3
Completed NCT00000587 - Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection Phase 2
Completed NCT00005273 - Pulmonary Complications of HIV Infection Study (PACS) N/A
Completed NCT00005303 - Effectiveness of AIDS Antibody Screening N/A
Completed NCT00005301 - Transfusion Safety Study (TSS) N/A
Completed NCT00001650 - Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients N/A
Withdrawn NCT00243568 - Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285 Phase 3
Recruiting NCT05031819 - Managing Hypertension Among People Living With HIV N/A
Completed NCT00394004 - Decision-Making of Hispanics and African-Americans With HIV/AIDS Participating in Clinical Trials N/A
Completed NCT01967940 - Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults Phase 3
Completed NCT01705574 - Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women Phase 3